AST Supports Congressional 21st Century Cures Initiative
AST is dedicated to advancing the future of transplant research and is proud to support the House Energy and Commerce Chairman's 21st Century Cures Initiative, which aims to accelerate the pace of the discovery, development, and delivery cycle, so that patients can get innovative new cures and treatments more quickly.
| Share this article:
Save the Date for the AST 2014 Fellows Symposium, September 19-21, 2014 in Grapevine, Texas
Don’t miss this highly popular educational meeting for young professionals starting a career in transplantation or immunology. The AST Fellows Symposium features an in-depth and interactive study of clinical transplantation, basic transplant immunobiology, and translational science in an informal setting, while providing important insights into career development and exceptional access to expert faculty. A limited number of travel grants are available for clinical and research fellows, and residents and trainees with an interest in solid organ transplantation.
Watch for registration opening in the coming weeks at www.myAST.org/fellows.
ESOT + AST Abstracts Due June 29: Submit Today!
ESOT + AST Joint Meeting
Personalized Transplantation: From New Diagnostics to New Therapeutics
October 17-19, 2014
Be a part of the program!
Submit your clinical, translational and basic abstracts on Novel Immune Monitoring and/or Diagnostics and Immunosuppression Strategies. Join the ESOT and AST as together we explore:
- New Options to Improve Immunosuppressive Therapy: Belatacept, Anti CD40 trial (ASKP1240), Anti- IL-6 and Tacrolimus formulations
- Novel Diagnostics: Donor DNA - Biomarker of Graft Injury, In vivo Live Imaging of the Immune Response and Tolerance Profile
- Novel Targets for Immunosuppression: B-cells, Plasma Cells and Complement
- Personalized Medicine: Technique and Technology: Sequencing for TCR Repertoire, Pharmacogenetics, Epigenetics, and Mixed Chimerism
- Cellular Strategies to Optimize Long Term Outcomes: T-regs, Mesenchymal Cells, Facilitator Cells
Upcoming Free Webinars and Webinars on Demand
The following webinars and journal club are scheduled for June; all are free to AST members and are available on demand after the live air date.
- Business of Transplantation Webinar on OPO Quality Programs, Wed., June 11; register online
- Journal Club on "A committed precursor to innate lymphoid cells", Tues., June 24, register online
AST also offers popular webinars and journal clubs on demand at www.myAST.org/T3, www.myAST.org/content/fellows-live-webinar-series, and www.myAST.org/journalclub.
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
RSVP for the AST Town Hall Meeting & Excellence in Transplantation Reception at the 2014 WTC
AST members are invited to take part in the annual member's business meeting, delivered in an exciting interactive town hall format. The Town Hall will take place during the upcoming World Transplant Congress (WTC) on Tuesday, July 29, 2014 at 5:45 PM on the second floor foyer of the Moscone West Convention Center. Join your colleagues and AST leadership to discuss the challenges and opportunities in the field of transplantation, learn how AST is positioned to meet these challenges/opportunities, and provide your feedback in shaping the future of the AST.
Immediately following the town hall, enjoy a casual gathering at the AST Excellence in Transplantation Reception, also on the second floor foyer of the Moscone West Convention Center. Indulge in delectable libations and hors d'oeuvres as you mingle with friends, award and grant recipients, and supporters.
Please submit your R.S.V.P. to attend both the town hall and reception here. Should you have any questions, please do not hesitate to contact the AST staff at info@myAST.org or 856-439-9986.
We look forward to seeing you in San Francisco!
These events made possible in part by Sanofi and Veloxis Pharmaceuticals
Polyclonal antithymocyte globulin and cardiovascular disease in kidney transplant recipients
Journal of the American Society of Nephrology
T-lymphocyte activation may contribute to atherosclerosis, the prevalence of which is increased in transplant patients. However, the cardiovascular consequences of polyclonal antithymocyte globulin (ATG)–induced immune modifications, which include alterations in T-cell subsets, are unknown. The following retrospective single-center study assesses whether ATG associates with an increased incidence of atherosclerotic events (CVEs) in kidney transplant patients.
Malignancy-related mortality following kidney transplantation is common
There is a paucity of studies describing malignancy-related mortality after kidney transplantation. To help quantify this, researchers extracted data for all kidney-alone transplant procedures performed in England between April 2001 and March 2012. Data linkage analysis was performed between Hospital Episode Statistics and the Office for National Statistics to identify all deaths occurring in this cohort.
Kidney transplantation with early corticosteroid withdrawal: Paradoxical effects at the central and peripheral skeleton
Journal of the American Society of Nephrology
The use of early corticosteroid withdrawal (ECSW) protocols after kidney transplantation has become common, but the effects on fracture risk and bone quality are unclear. In the following, 47 first-time adult transplant recipients managed with ECSW into a 1-year study to evaluate changes in bone mass, microarchitecture, biomechanical competence, and remodeling with dual energy x-ray absorptiometry (DXA), high-resolution peripheral quantitative computed tomography (HRpQCT), parathyroid hormone (PTH) levels, and bone turnover markers obtained at baseline and 3, 6, and 12 months post-transplantation.
Was Sarah Murnaghan treated justly?
Lung transplantation is a potentially life-saving procedure for patients with irreversible lung failure. Five-year survival rates after lung transplantation are >50% for children and young adults. But there are not enough lungs to save everyone who could benefit. In 2005, the United Network for Organ Sharing developed a scoring system to prioritize patients for transplantation. That system considered transplant urgency as well as time on the waiting list and the likelihood that the patient would benefit from the transplant.
Missed last week's issue? See which articles your colleagues read most.